"Transformative" Dupilumab Set For Third Quarter Filing In Atopic Dermatitis

SOLO studies are "first Phase III studies of a systemic therapy to demonstrate a significant improvement in moderate-to-severe atopic dermatitis."

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet